- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
A panel of experts discuss navigating access challenges in CLL treatment.
EP: 1.Recent Trends and Innovations in the Management of CLL
EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors
EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment
EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy
EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence
EP: 6.Optimizing Therapy Sequencing in CLL
EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
EP: 8.Decision-Making in CLL: The Role of Real-World Evidence
EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL
EP: 13.Patient Access Advocacy for BTK Inhibitors
EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Video content above is prompted by the following question(s):
- What are the major access challenges in CLL treatment, and how can they be overcome?
- How do payer policies and clinical pathways affect the clinical decision-making process for CLL treatments?
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL
July 7th 2025Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.
Read More
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy
June 26th 2025Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Read More
